Forconi, Francesco (2018) Five years of ibrutinib in CLL. Blood, 131 (21), 2280-2281. (doi:10.1182/blood-2018-03-837864).
Abstract
The study by Ahn et al in this issue of Blood is an important clinical update with a 5-year follow-up on efficacy and toxicity of single-agent ibrutinib, an inhibitor of B-cell receptor (BCR) pathway–associated Bruton tyrosine kinase (BTK), in patients with chronic lymphocytic leukemia (CLL).
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.